Sequential Adebrelimab Combined With Apatinib as Consolidation Therapy Following Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Single-Arm, Multicenter Phase II Clinical Study
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Adebrelimab (Primary) ; Rivoceranib
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 17 Jan 2025 New trial record